Janux Therapeutics (NASDAQ:JANX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Janux Therapeutics (NASDAQ:JANX) had its price objective boosted by research analysts at Stifel Nicolaus from $70.00 to $115.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 72.07% from the stock’s current price.

Several other equities analysts have also recently weighed in on JANX. Wedbush reissued an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday. BTIG Research upped their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Leerink Partners began coverage on Janux Therapeutics in a report on Friday, November 22nd. They issued an “outperform” rating and a $79.00 price target for the company. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and an average price target of $79.90.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $66.84 on Tuesday. Janux Therapeutics has a twelve month low of $7.79 and a twelve month high of $71.25. The stock has a market capitalization of $3.51 billion, a PE ratio of -57.12 and a beta of 3.29. The stock has a 50-day simple moving average of $49.83 and a 200 day simple moving average of $45.81.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics’s revenue was down 82.6% on a year-over-year basis. As a group, equities research analysts forecast that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Activity

In related news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the stock in a transaction dated Friday, October 18th. The shares were bought at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the purchase, the director now owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. This trade represents a 14.78 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the sale, the insider now owns 6,887 shares in the company, valued at approximately $318,454.88. This trade represents a 12.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 460,610 shares of company stock worth $21,583,666. Company insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of large investors have recently bought and sold shares of the business. Plato Investment Management Ltd grew its position in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the last quarter. Amalgamated Bank grew its position in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the last quarter. Summit Securities Group LLC bought a new stake in Janux Therapeutics during the 2nd quarter worth approximately $29,000. Finally, Virtu Financial LLC grew its position in Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after acquiring an additional 2,419 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.